Since HER2-low is it’s own breast cancer entity now, this retrospective look at outcomes for women receiving targeted therapies such as CDK4/6 inhibitors, everolimus, or alpelisib in addition to endocrine therapy for metastatic hormone receptor-positive breast cancer reports HER2-low status appeared no have no bearing on outcomes. | Mouabbi, JAMA Netw Open 2023
